Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for UroGen Pharma (URGN) over the last 4 years, with Q3 2025 value amounting to $122.1 million.

  • UroGen Pharma's Non-Current Debt rose 33.03% to $122.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 33.03%. This contributed to the annual value of $121.7 million for FY2024, which is 2352.39% up from last year.
  • Per UroGen Pharma's latest filing, its Non-Current Debt stood at $122.1 million for Q3 2025, which was up 33.03% from $122.5 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Non-Current Debt ranged from a high of $122.5 million in Q2 2025 and a low of $70.8 million during Q1 2022
  • Moreover, its 4-year median value for Non-Current Debt was $98.3 million (2023), whereas its average is $100.7 million.
  • As far as peak fluctuations go, UroGen Pharma's Non-Current Debt soared by 3834.06% in 2023, and later plummeted by 49.14% in 2024.
  • Quarter analysis of 4 years shows UroGen Pharma's Non-Current Debt stood at $97.5 million in 2022, then increased by 1.04% to $98.6 million in 2023, then rose by 23.52% to $121.7 million in 2024, then grew by 0.31% to $122.1 million in 2025.
  • Its Non-Current Debt was $122.1 million in Q3 2025, compared to $122.5 million in Q2 2025 and $122.1 million in Q1 2025.